VIOLIN Logo
VO Banner
Search: for Help
About
Introduction
Statistics
VIOLIN News
Your VIOLIN
Register or Login
Submission
Tutorial
Vaccine & Components
Vaxquery
Vaxgen
VBLAST
Protegen
VirmugenDB
DNAVaxDB
CanVaxKB
Vaxjo
Vaxvec
Vevax
Huvax
Vaccine Mechanisms
Vaximmutordb
Vaxism
Vaxar
Vaccine Literature
VO-SciMiner
Litesearch
Vaxmesh
Vaxlert
Vaccine Design
Vaxign
Community Efforts
Vaccine Ontology
ICoVax 2012
ICoVax 2013
Advisory Committee
Vaccine Society
Vaxperts
VaxPub
VaxCom
VaxLaw
VaxMedia
VaxMeet
VaxFund
VaxCareer
Data Exchange
V-Utilities
VIOLINML
Help & Documents
Publications
Documents
FAQs
Links
Acknowledgements
Disclaimer
Contact Us
UMMS Logo

Caprine herpesvirus type 1 (CpHV-1)

Table of Contents
  1. General Information
    1. NCBI Taxonomy ID
    2. Introduction
  2. Vaccine Information
    1. BoHV-4-A-gD(cp)gD(106)ΔTK
  3. References
I. General Information
1. NCBI Taxonomy ID:
39944
2. Introduction
Caprine herpesvirus type 1 (CpHV-1) is an alphaherpesvirus causing genital disease leading to abortion in adult pregnant goats and a systemic disease with high morbility and mortality in kids. CpHV-1 infection also represents a valuable large animal model for human herpesvirus induced genital disease, exploitable for pathogenic studies, new vaccines and antiviral molecules testing (Donofrio et al., 2013).
II. Vaccine Information
1. BoHV-4-A-gD(cp)gD(106)ΔTK
a. Vaccine Ontology ID:
VO_0004685
b. Type:
Recombinant vector vaccine
c. Status:
Research
d. Host Species for Licensed Use:
Baboon
e. Preparation
The bovine herpesvirus 4 (BoHV-4) based vector derived from an apathogenic isolate of BoHV-4 was used to express the immunodominant CpHV-1 glycoprotein D (BoHV-4-A-gD(cp)gD(106)ΔTK) (Donofrio et al., 2013).
f. Immunization Route
Intramuscular injection (i.m.)
g. Goat Response
  • Vaccination Protocol: Goats were vaccinated with BoHV-4-A-gD(cp)gD(106)ΔTK (Donofrio et al., 2013).
  • Vaccine Immune Response Type: VO_0003057
  • Immune Response: No clinical signs were evident but a good titer of serum neutralizing antibodies was produced in all inoculated animals (Donofrio et al., 2013).
  • Challenge Protocol: A challenge experiment was performed in a new group of animals using a highly pathogenic dose of CpHV-1 (Donofrio et al., 2013).
  • Efficacy: All the vaccinated goats with BoHV-4-A-gD(cp)gD(106)ΔTK were protected toward CpHV-1 induced genital disease respect to the unvaccinated control goat who showed typical vaginal lesions with a high grade of clinical score as well as a long lasting viral shedding (Donofrio et al., 2013).
III. References
1. Donofrio et al., 2013: Donofrio G, Franceschi V, Lovero A, Capocefalo A, Camero M, Losurdo M, Cavirani S, Marinaro M, Grandolfo E, Buonavoglia C, Tempesta M. Clinical protection of goats against CpHV-1 induced genital disease with a BoHV-4-based vector expressing CpHV-1 gD. PloS one. 2013; 8(1); e52758. [PubMed: 23300989].